Roche licenses two of Inovio's early-stage DNA vaccines
This article was originally published in Scrip
Roche has bolstered its early-stage pipeline by entering a collaboration with small US biotech company Inovio Pharmaceuticals. Roche is paying $10m upfront for exclusive worldwide rights to two of Inovio's preclinical immunotherapies targeting prostate cancer and hepatitis B.
You may also be interested in...
Deal activity over the past seven days sees Roche knock back Inovio a second time, Regeneron plan for its future via an alliance with Adicet Bio, Amgen supplement its preclinical pipeline with a candidate from Advaxis, and Pfizer shore up its gene therapy ambitions with an acquisition.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.